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Purpose: To investigate if study design factors such as randomization, multi-center versus 
single center evidence, institutional surgical volume, and patient selection affect the outcomes 
for endovascular repair (EVAR) versus open surgical repair (OSR). Finally, we investigate 
trends over time in EVAR versus OSR outcomes.
Methods: Search strategies for comparative studies were performed individually for: OVID’s 
MEDLINE, EMBASE, CINAHL, HAPI, and Evidence Based Medicine (EBM) Reviews (including 
Cochrane DSR, ACP Journal Club, DARE and CCTR), limited to 1990 and November 2006.
Results: Identiﬁ  ed literature: 84 comparative studies pertaining to 57,645 patients. These 
include 4 randomized controlled trials (RCTs), plus 2 RCTs with long-term follow-up. The 
other 78 comparative studies were nonrandomized with 75 reporting perioperative outcomes, of 
which 16 were multi-center, and 59 single-center studies. Of the single-center studies 31 were 
low-volume and 28 were high-volume centers. In addition, 5 studies had all patients anatomi-
cally eligible for EVAR, and 8 studies included high-risk patients only. Finally, 25 long term 
observational studies reported outcomes up to 3 years.
Outcomes: Lower perioperative mortality and rates of complications for EVAR versus OSR 
varied across study designs and patient populations. EVAR adverse outcomes have decreased 
in recent times.
Conclusion: EVAR highlights the problem of performing meta-analysis when the experience 
evolves over time.
Keywords: abdominal aortic aneurysm, endovascular repair, open surgical repair, systematic 
review, meta-analysis
Introduction
Two recent reviews have described the relative outcomes of endovascular repair 
(EVAR) versus open surgical repair (OSR) (Drury et al 2005; Ho et al 2006) and of 
EVAR alone (Franks et al 2007) for abdominal aortic aneurysms (AAA) based on 
evidence from both randomized control trials (RCTs) and nonrandomized control 
trials (nRCTs). Despite these recent reviews, there are limitations in the accumulated 
evidence for an assessment comparing EVAR and OSR. As the authors suggest, the 
major differences between the RCTs and the nRCTs relate to differences in baseline 
characteristics of the patient populations and overall study design. While the recent 
reviews have cautioned the interpretation of the differential outcomes of EVAR versus 
OSR found in RCT compared to nRCTs, they do not assess the degree to which the 
imbalances or different study design impact relative outcomes.
For example, patients in RCTs tend to have lower ASA risk levels than patients in 
nRCTs, and the average ASA risk tends to be higher for EVAR than OSR patients in 
nRCTs (Sbarigia et al 2005). This baseline imbalance for AAA repair has continued 
ever since EVAR was ﬁ  rst introduced to beneﬁ  t patients with AAA who were 
physiologically at high risk for OSR or who were anatomically suitable for EVAR 
(Parodi et al 1991). Despite the focus on high risk patients, the beneﬁ  ts of EVAR in Vascular Health and Risk Management 2008:4(5) 1012
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lower risk patients has also recently been established in two 
large RCTs, DREAM (Prinssen et al 2004) and EVAR-1 
(Greenhalgh et al 2004). Despite these two landmark trials, 
only one small RCT has been completed to assess differences 
in quality of life between EVAR and OSR patients (Soulez 
et al 2005). In order to compare and contrast the outcome 
evidence of EVAR and OSR in RCTs and nRCTs, differences 
in patient baseline risk levels and the degree to which these 
risk levels differ between EVAR and OSR in observational 
studies need to be investigated.
A major limitation of the recent reviews is the inclusion 
of studies that should have otherwise been excluded. For 
example, some studies are multi-center in nature and the 
meta-analysis includes the results of the multi-center stud-
ies and the redundant constituent single center evidence 
(Brewster et al 1998; Sicard et al 2001; Makaroun et al 
2002; Matsumura et al 2003). This is particularly evident 
with the large device trials, the Lifeline Registry (LREAR 
2001) and the Eurostar Registry (Buth and Parodi 1999). 
In addition, other evidence that should be excluded is the 
studies that include early evidence from the Ancure multi-
center trial, even though the device was temporarily removed 
from the market for underreporting complications (Moore 
et al 2001).
Interestingly, EVAR was originally intended for high 
risk patients, but there has been little cumulative evidence 
reported for high risk patients only (Sbarigia et al 2005). 
To address the beneﬁ  ts to high risk patients only, a review 
of studies where both EVAR and OSR patients are deemed 
at high medical risk should be the starting point. Similarly, 
EVAR is usually offered to anatomically suitable candidates. 
Yet, no review has isolated studies where both EVAR and 
OSR patients are anatomically suitable for EVAR. To include 
anatomically suitable patients for a comparative review 
would eliminate a signiﬁ  cant bias in terms of the effects of 
vasculature on surgical outcomes (Welborn et al 2005).
A further bias is added in reviews if the authors do not 
incorporate inclusion criterion based on treatment volumes or 
control for treatment volume in the analysis. This is important 
because most centers have low annual volume and treatment 
volumes have been shown to be related to treatment outcomes 
for endovascular repair (Bush et al 2006) as well as other 
cardiac procedures (Franks et al 2007). Accordingly, it is 
important to compare relative outcomes for EVAR and OSR 
adjusting for different treatment volumes.
Finally, EVAR technology has been evolving over time 
due to new device generations and improvements in surgical 
techniques such as crossover grafts (Moise et al 2006). 
The recent review of EVAR alone studies described a 
decreasing rate of mortality over time (Franks et al 2007). 
Reviews that ignore the potential impact of time trends on 
the relative rate of mortality or systemic events of EVAR 
over time may potentially introduce bias.
The objectives of this systematic literature review were 
to address issues left unanswered by earlier reviews, such as: 
1) to describe and compare the patient characteristics from 
the identiﬁ  ed observational and randomized controlled trials 
of EVAR and OSR patients; 2) to examine differences in 
outcome measures between the treatment groups by study 
design and characteristics; and 3) to evaluate relative trends 
in mortality and endoleak rates over time. More speciﬁ  cally, 
this report investigated the effects of baseline characteristics 
imbalance, study design (ie, nRCT versus RCT), center status 
(ie, multi-center versus single center), patient risk status, 
EVAR suitability, treatment volume (ie, low versus high), 
and year of study publication on patient outcomes.
Methods
Literature search
Literature search strategies were developed to identify papers 
comparing EVAR to OSR. Strategies for each of the follow-
ing databases were developed and performed individually 
in OVID’s: MEDLINE, EMBASE, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), Health 
and Psychosocial Instruments (HAPI), and Evidence-Based 
Medicine (EBM) Reviews (including Cochrane Database of 
Systematic Reviews (CDSR), ACP Journal Club, Database 
of Abstracts of Reviews of Effects (DARE) and Cochrane 
Central Register of Controlled Trials (CCTR)). Results 
were limited to human and English language studies pub-
lished between 1990 and November 2006 inclusive. Identiﬁ  -
cation of duplicate citations was completed using Reference 
Manager (v.10; Thomson ResearchSoft, Philadelphia, PA, 
USA). RCTs, controlled clinical trials, comparative obser-
vational studies, case series studies, and population-based 
registries assessing the efﬁ  cacy and/or safety of EVAR versus 
OSR were all included in the review.
Titles and abstracts (when available) of all search results 
were screened using predeﬁ  ned criteria in order to identify 
publications that discussed the use of EVAR and OSR for the 
management of AAA. When it could not be determined from 
the information available whether an item met the inclusion 
criteria or not, the article was reviewed in full-text.
Inclusion criteria included nonruptured AAA repair, of 
at least a mean AAA diameter of greater than 5 cm, and a 
publication date from 1990 onwards. Citations were excluded Vascular Health and Risk Management 2008:4(5) 1013
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if they reported a mixed patient population including patients 
with thoracic-abdominal aneurysms, iliac aneurysms, rup-
tured or infected aorta, emergency aortic repair. No restriction 
based on clinical study design was used and nonrandomized 
trials and patient registries were included. All relevant or 
potentially relevant studies were then retrieved in full-text.
Review of full-text articles was conducted to identify 
publications with unique patient data using preset criteria. 
Also, clinical studies regarding the FDA-approved clinical 
trials related to the Ancure device (Guidant) were identiﬁ  ed 
and excluded from further analysis due to the potential under-
reporting of device related complications (Bren 2003).
Data extraction
For unique comparative clinical studies, data were abstracted 
using a standard form to record details of the study design and 
methods, patient baseline characteristics, technical aspects of 
EVAR and OSR and outcome measures of interest according 
to SVS reporting standards (Chaikof et al 2002).
Clinical outcomes were obtained from studies which 
described 30 day and post 30 day events. When longer term 
cumulative evidence was available (30 days), 30 day events 
were not included in the analysis of the long term outcome 
data. Studies were classiﬁ  ed as multi-center or single center. 
Where studies examined outcomes from a single center over a 
period of time greater than one year, annual treatment volume 
was estimated by dividing the number of patients in the study 
by the enrollment duration in years. Further, after determin-
ing the median surgical volume of institutions performing 
EVAR, surgical volume was divided into two categories: 
low volume institutions (identiﬁ  ed as having, on average, 
less than 30 patients per year) and high volume institutions 
(completed 30 or more procedures per year).
Studies including only high-risk surgical patients were 
also identiﬁ  ed. High-risk patients were classiﬁ  ed as high-
risk if any one of the following characteristics was present: 
age 80, ASA III or IV, or an existing systemic complication 
(cardiac, pulmonary, renal) (Hollier et al 1992) If available, 
further information was extracted from the studies regarding 
the suitability of patients who received OSR as to whether 
they could have received EVAR.
Statistical analysis
Statistical analysis was carried out using Excel 2002 
(Microsoft Corp., Redmond, WA, USA) and Stata (StataCorp., 
College Station, TX, USA) with comparison of dichotomous 
outcomes expressed as odds ratios (OR). An OR less than 
1 indicated a lower rate in EVAR than OSR. Continuous 
variables were analyzed using weighted mean differences 
(WMD). A WMD less than zero indicated a lower rate in 
EVAR than OSR. A level of signiﬁ  cance (α) of 0.05 was 
used to indicate statistical signiﬁ  cance.
Meta-regression analyses (including a random effect) 
were performed using Stata metareg command to test if there 
were differences in outcomes between EVAR and OSR with 
respect to study enrolment time. Where there were multi-year 
enrolment periods, the middle of the time period was used as 
the independent variable. Trends in comparative outcomes 
which were analyzed and included were operative mortality, 
systemic and vascular complications, and adjuvant proce-
dures. Trends in EVAR speciﬁ  c outcomes such as the rate 
of endoleaks (I–IV) and conversion were also investigated. 
A level of signiﬁ  cance (α) of 0.05 was used to indicate sta-
tistical signiﬁ  cance in the trend coefﬁ  cient.
Results
Literature search
The literature search initially completed on 20 May 2005 and 
updated on 28 Nov 2006 identiﬁ  ed a combined total of 3,946 
unique citations (see Figure 1). The following evaluation is 
based on 84 comparative studies, containing unique patient 
data comparing EVAR to OSR.
Study characteristics
These 84 studies included 4 randomized controlled trials of 
which all 4 reported short-term outcomes (Cuypers et al 2001; 
Greenhalgh et al 2004; Prinssen et al 2004; Soulez et al 2005) 
and 2 reported subsequent long-term outcomes (Blankensteijn 
et al 2005; Greenhalgh 2005). The other 78 comparative 
studies were observational evaluations (nRCT) (3 long term 
only) (Birch et al 2000; Kibbe et al 2003; LREAR 2005).
Overall, the identiﬁ  ed studies contained data pertaining 
to 59,188 patients. In the 75 observational studies with 
perioperative outcomes reported (initial 30 days), there 
were 16,407 and 41,238 patients receiving EVAR and 
OSR, respectively. Of these observational studies, 16 were 
categorized as multi-center (Zarins et al 1999; Beebe et al 
2001; Criado et al 2003; Matsumura et al 2003; Akkersdijk 
et al 2004; Anderson et al 2004; Carpenter and Endologix 
2004; Greenberg et al 2004; Forbes et al 2005; Hua et al 
2005; Leon et al 2005; LREAR 2005; Bush et al 2006; 
Mendonca et al 2005; Sandridge et al 2006; Wald et al 
2006). The other 59 papers were single center evaluations 
subdivided based on annual surgical volume of 30 cases per 
year, identiﬁ  ed 31 low volume centers (de Virgilio et al 1999; 
Kahn et al 1999; Seiwert et al 1999; Treharne et al 1999; Vascular Health and Risk Management 2008:4(5) 1014
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Becquemin et al 2000; Cohnert et al  2000; Malina 
et al 2000; Sangiorgi et al 2001; Berman et al 2002; 
Davies et al 2002; Forbes et al 2002; Ligush et al 2002;
Van Sambeek et al 2002; Gawenda et al 2003; Hansman et al 
2003; Patel et al 2003; Ting et al 2003; Turnipseed et al 2003; 
Ballard et al 2004; Garcia-Madrid et al 2004; Zeebregts et al 
2004; Aarts et al 2005; Borchard et al 2005; Gouefﬁ  c et al 
2005; Hayter et al 2005; Iannelli et al 2005; Rosenberg 
et al 2005; de Donato et al 2006; Manis et al 2006; Vogel 
et al 2005; Parmer et al 2006), and 28 high volume centers 
(Baxendale et al 1996; Du Toit et al 1998; Ceelen et al 1999; 
Scharrer-Pamler et al 1999; Clair et al 2000; Galle et al 
2000; Odegard et al 2000; Bertrand et al 2001; May 
et al 2001; Rowlands and Homer-Vanniasinkam 2001; 
Wijnen et al 2001; Carpenter et al 2002; Teufelsbauer 
et al 2002; Arko et al 2003; Decker et al 2003; Dias et al 
2003; Dryjski et al 2003; Jordan et al 2003; Junnarkar et al 2003; 
Aho et al  2004; Angle et al 2004; Cao et al 2004; Elkouri 
et al 2004; Prault et al 2004; Watson et al 2004; Mehta et al 
2005; Englberger et al 2006; Park et al 2006).
Five studies included information regarding patients that 
were surgically suitable for either procedure (Becquemin et al 
2000; Forbes et al 2002; Dias et al 2003; Gawenda et al 2003; 
Garcia-Madrid et al 2004), 8 studies speciﬁ  cally examined 
the efﬁ  cacy of high-risk patients only (Du Toit et al 1998; 
Carpenter et al 2002; Forbes et al 2002; Patel et al 2003; 
Iannelli et al 2005; Mendonca et al 2005; de Donato et al 
2006; Parmer et al 2006) Long-term outcomes (30 days) 
were reported in 25 observational studies with long term 
comparative outcomes of up to 3 years mean follow- up 
(Zarins et al 1999; Becquemin et al 2000; Birch et al 2000; 
Cohnert et al 2000; Beebe et al 2001; May et al 2001; 
Sangiorgi et al 2001; Carpenter et al 2002; Arko et al 
2003; Criado et al 2003; Dias et al 2003; Kibbe and 
3946 Unique citations
Titles & abstracts reviewed
AAA rupture, thoracic aneurysm, other
1558 single arm or non-EVAR comparison (39.5%)
EVAR
EVAR
246 citations (6.2%)
Comparative Information
EVAR vs OSR
EVAR vs OSR EVAR vs OSR
EVAR vs OSR
EVAR vs OSR
EVAR vs OSR
comparative studies
OSR
BMT
OSR vs BMT
89 articles (2.2%)
23 articles (0.6%)
10 articles (0.3%) 40 articles (1.0%) 84 articles (2.1%)
134 articles (3.4%)
157 articles (4.0%)
Randomized & nonrandomized
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comments, reviews, case reports, letters/editorials Full Text Screening: potential comparative studies
1804 elective repair of AAA by EVAR (45.7%)
Further title & abstract screening
2142 articles excluded (54.3%)
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Based on full text review
10 ancure endograft studies
Overlap of patient recruitment 6 randomized/78 nonrandomized
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Unique primary comparative studies
Duplicate patient information
Comparative studies
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Matsumura 2003; Ting et al 2003; Ballard et al 2004; Cao 
et al 2004; Elkouri et al 2004; Garcia-Madrid et al 2004; 
Greenberg et al 2004; Zeebregts et al 2004; Gouefﬁ  c et al 
2005; LREAR 2005; Mendonca et al 2005; Bush et al 2006; 
Carpenter 2006; Parmer et al 2006).
Differences between the EVAR and OSR treatment 
groups for various baseline characteristics and estimates of 
short-term mortality, systemic complications, procedural 
outcomes, local/vascular complications, and EVAR speciﬁ  c 
outcomes are described below.
Differences between patient characteristics and relative 
outcomes are discussed in the following order: RCTs ver-
sus observational studies, multi-center versus single center 
observational studies, studies that have patients that are 
suitable for both procedures (EVAR and OSR), studies with 
only high risk patients, and ﬁ  nally high volume versus low 
volume single center evidence.
Patient characteristics
RCT vs observational studies
As shown in Table 1, patients enrolled in the EVAR and 
OSR arms of the 4 RCTs identiﬁ  ed in this review had 
similar baseline characteristics except for pulmonary history 
(OR = 1.81, P  0.05). In contrast, in nonrandomized stud-
ies, patients receiving EVAR were more likely to be male 
(OR 1.64), have higher ASA III and IV ratings (OR 1.33, 
1.49, respectively), and less likely to be ASA I or II (OR 
0.20, 0.72). In all observational studies, EVAR patients had 
a higher surgical risk with greater baseline comorbidities 
than in OSR patients.
Multi-center vs single center
observational studies
In single or multi-center institutions, patients receiving 
EVAR were more likely than patients receiving OSR to have 
comorbidities such as smoking history, diabetes, hyperlipid-
emia, cardiac disease, and peripheral vascular disease (PVD) 
and less likely to have hypertension (Table 1). No statistical 
difference existed for AAA diameter and age for multi-center 
or single center evidence. Within the single center evidence, 
more patients had higher level of ASA in EVAR than OSR 
(ASA I to IV: OR 0.20, 0.72, 1.33, 2.38). In patients that 
received EVAR, there were more males, a greater number 
of individuals with a smoking history, more patients with 
diabetes, cardiac disease, peripheral vascular disease, and 
less hypertension. Multi-center evidence included less 
patients receiving EVAR that have cardiovascular disease, 
pulmonary, or renal disease, while single center evidence 
reported the opposite. Fewer patients had stroke in EVAR in 
multi-center studies, and more had hyperlipidemia in EVAR 
in single center studies.
Studies with patients anatomically suitable
for both EVAR and OSR
Only 5 studies stated that both EVAR and OSR patients were 
anatomically suitable for EVAR. While no statistical differ-
ences were found between AAA diameter and age, there 
was a much higher rate of ASA III and IV (OR 2.93, 12.34, 
respectively) in the EVAR patients than in the OSR patients 
as compared to the other study designs.
Studies with only high risk patients
When examining the baseline characteristics of the 8 stud-
ies that had high risk patients only, there were no statistical 
baseline difference in AAA diameter and age. As observed 
with EVAR studies reporting patient suitability, there were 
statistically signiﬁ  cantly more ASA IV patients that received 
EVAR than in all nRCTs (OR 10.80).
High volume vs. low volume centers
The differences in baseline characteristics between the EVAR 
and OSR patients were still apparent when the single center 
studies are stratiﬁ  ed based on their estimated procedural 
volume (Table 1). In institutions with high volume, patients 
receiving EVAR were also more likely than patients receiv-
ing OSR to have comorbidities such as smoking history, 
diabetes, hyperlipidemia, cardiac disease, and peripheral 
vascular disease (PVD) and less likely to have hypertension 
(Table 1).
Comparison of perioperative mortality 
and complications
RCT vs. observational studies
In the 75 nRCT studies, lower 30-day mortality existed 
in EVAR than OSR. The mortality difference reported in 
the nRCTs and in the RCTs was OR = 0.429 and 0.336, 
respectively (Table 2). Of all of the possible study designs 
and patient populations, RCTs reported the lowest OR for 
mortality (0.336). Within the published RCTs, there were no 
statistical differences between EVAR and OSR with respect 
to the occurrence of a MI, CHF, or arrhythmia, however, not 
all clinical outcomes were reported in the published papers 
(Table 2). In all designs lower rates of systemic complica-
tions were reported for all measures in EVAR treated patients 
compared to the OSR group, with the exception of limb 
ischemia which was higher in EVAR (OR 1.866).Vascular Health and Risk Management 2008:4(5) 1016
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Multi-center vs single center
observational studies
Similar mortality results existed in multi-center versus 
single center evidence. In addition, the OR of all complica-
tions for both multi-center and single center studies were 
less than 1, indicating the beneﬁ  t of EVAR vs OSR, in 
terms of all systemic complications (cardiac, pulmonary, 
renal, stroke, and ischemia). In general, the multi-center 
studies reported lower OR for EVAR vs OSR for cardiac 
and renal complications, similar OR for pulmonary 
complications. The evidence for stroke and ischemia 
was mixed.
Studies with patients anatomically suitable
for both EVAR and OSR
No statistical difference between EVAR and OSR existed in 
mortality in anatomically suitable patients. This is important 
considering that the difference between EVAR and OSR 
baseline characteristics was the highest in this patient popu-
lation. There was insufﬁ  cient evidence to compare systemic 
complications.
Studies with only high risk patients
No statistical difference existed in mortality in high-risk 
patients, despite ASA IV patients being 10.80 times more 
likely to receive EVAR than OSR. Similarly, there were less 
complications in EVAR than OSR for cardiac (OR 0.076) 
and pulmonary complications (OR 0.075) (Table 2).
High volume vs. low volume centers
Similar differences in mortality existed in high volume versus 
low volume centers, when compared to all observational 
studies. In addition, there appeared to be little difference 
in systemic complications between high volume and low 
volume centers. This is despite high volume centers having 
a higher level of ASA IV patients, while low volume centers 
reported higher levels of other comomorbidities with the 
exception of pulmonary disease.
Surgical outcomes and local/vascular 
complications
Across all types of studies, and treatment volume risk status, 
surgical outcomes were better for EVAR in terms of OR time, 
Table 1 Difference in patient characteristics by study design and risk status
RCT nRCT Multi-center Single center Low volume High volume Suitable High risk
Studies 4 75 16 59 31 28 5 8
# EVAR patients 791 16,407 12,036 4,371 1,496 2,875 260 332
# OSR patients 752 41,238 36,443 4,795 1,752 3,043 235 352
WMD. WMD. WMD. WMD. WMD. WMD. WMD. WMD.
Age −0.43 −2.02 −2.27 −1.49 −2.03 −1.01 −1.17 −2.84
AAA diameter (cm) −0.04 0.27 0.15 0.36 0.24 0.54 −0.02 0.16
Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio
Male % 1.13 1.64* 1.76* 1.44* 1.19* 1.62* 1.23 1.66*
ASA I 0.82 0.20* n.a. 0.20* 0.21* n.a. n.a. n.a.
ASA II 1.21 0.72* n.a. 0.72* 0.52* 1.19 0.09* n.a.
ASA III 1.14 1.33* 1.01 1.33* 1.06 1.53* 2.93* 0.39*
ASA IV n.a. 1.49* 1.04 2.38* 3.87* 2.13* 12.34* 10.80*
Smoking history 1.17 1.19* 1.20* 1.22* 0.83* 1.57* 1.81* 0.37*
Hypertension 1.05 0.93* 0.92* 0.85* 0.83* 0.86* 1.66* 0.97
Diabetes 0.79 1.28* 1.22* 1.42* 1.18 1.58* 1.15 1.74
Hyperlipidemia 0.93 1.22* 0.97 1.61* 1.29* 1.80* 2.14* n.a.
Cardiac Disease 0.95 1.84* 2.25* 1.38* 1.13 1.56* 1.39* 1.39*
CVD n.a. 0.89 0.68* 1.28* 0.98 1.38* n.a. n.a.
Pulmonary 1.81 * 1.01 0.87* 1.43* 1.64* 1.34* 1.58* 1.19
PVD n.a. 1.28* 1.21* 1.39* 0.77 2.33* n.a. 1.25
Renal 0.77 0.97 0.79* 1.27* 1.13 1.31* 0.72 1.15
Stroke n.a. 0.48 0.20* 0.92 n.a. 0.72 n.a. n.a.
Notes: *statistically signiﬁ  cant: p-value 0.05. Both WMD and Odds Ratio were calculated with patient weights.
Abbreviations: n.a., not available; WMD, weighted mean difference; EVAR-OSR, Odds Ratio (EVAR/OSR).Vascular Health and Risk Management 2008:4(5) 1017
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blood loss, ICU length of stay (LOS), and total hospital, but 
these differences were not always statistically signiﬁ  cant 
(Table 3,4).
EVAR-speciﬁ  c outcomes
A meta-analysis of the studies reporting endoleak data is 
presented in Table 5.
Endoleaks
The rate of  type 1 endoleaks was similar across study designs 
and patient populations, but was absent in the RCTs and 
highest in the suitable patient group. In contrast, the rate of 
type 2 endoleaks was lowest in the suitable patient group and 
in the RCTs.Type 3 and type 4 endoleaks, conversion, graft 
kinks, or folds are rare.
The rate of graft obstruction is high in the suitable patient 
group, and the rate of graft migration was highest in the high 
risk group.
Trends in endoleaks and ischemia
over time
Examining the reported rate against the mid recruitment time 
of the study demonstrates that Type 1 endoleaks have been 
decreasing over time (Table 6). In comparison, the rate of 
type 2 endoleaks is relatively constant. Based on the study 
reports there has been a statistical increase in the rate of type 3 
endoleaks over time (but this is the result of one outlier), 
and a decrease in the rate of type 4 endoleaks. Finally, the 
difference in the rate of limb ischemia has been decreasing 
over time (P  0.01).
Table 2 Mortality and systemic complications
RCT nRCT Multi-center Single center Low volume High volume Suitable High risk
Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio Odds ratio
Studies 4 75 16 59 31 28 5 8
Mortality 0.336* 0.429* 0.437* 0.539* 0.508* 0.555* 0.797 0.517
Cardiac
 Myocardial  infarction 0.655 0.401* 0.250* 0.463* 0.178 0.486* ––
  Congestive heart failure 0.159 0.551* – 0.622 – 0.736 – –
 Arryhthmia – 0.198* 0.391 0.216 0.107* 0.262* ––
 Angina – 0.047* – 0.051* ––– –
 Unspeciﬁ  ed 0.752 0.473* 0.383* 0.661* 0.759 0.506* 0.611 0.076*
Pulmonary
 Failure – 0.268* 0.226* 0.263* 0.267* 0.268* ––
 Edema – 0.375 – 1.233 – – –
 Pneumonia – 0.201* 0.242* 0.164* 0.270 0.160* – 0.306
 Pulmonary  embolism – 0.127* 0.657 0.050* – 0.057* ––
 Unspeciﬁ  ed – 0.219* 0.204* 0.255* 0.219* 0.282* 0.105* 0.075*
 Major 0.246* 0.288* 0.427* 0.126* – 0.168* ––
 Moderate 0.265* –– – – – ––
Renal
 Permanent  failure – 0.290* 0.102* 0.634 0.000 3.098* ––
 Temporary  failure 1.018 0.553* 0.258* 0.717 0.479 0.859 – 0.322
 Unspeciﬁ  ed – 0.396* 0.391* 0.422* 0.593 0.368* 0.483 0.314
Stroke and ischemia
 Stroke – 0.476 0.196 * 0.916 – 0.715 – –
   Transient ischemia 
Attacks
0.321* –– – – – ––
 Bowel/colon  ischemia 2.047 0.302* 0.197 0.328* 0.871 0.238* ––
 Limb  ischemia – 1.866* – 2.134* 2.711 2.032* ––
 Spinal  ischemia 0.506 – – 0 – – – –
 Other  ischemia – 0.511 – 0 – – – 0.822
Notes: *statistically signiﬁ  cant: p-value 0.05. – : not available,
WMD (weighted mean difference) (EVAR-OSR). Odds ratio (EVAR/OSR). Both WMD and odds ratio were calculated with patient weights.Vascular Health and Risk Management 2008:4(5) 1018
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In addition, when the trends in the difference in peri-
operative mortality were determined against the mid-enrolment 
time of the study, there was a small but statistically signiﬁ  cant 
difference that persisted over time. The mortality difference has 
been changing at a rate of 0.066% per year (P  0.001).
Mid-term mortality
No statistical difference in mid-term mortality was found 
between EVAR and OSR over time. This evidence was 
based on a total of 6,289 patients with EVAR and 3,547 who 
received OSR and were followed in comparative nRCT up 
to a maximum of 36 months. In RCTs, 914 patients received 
EVAR, and 784 patients received OSR with a mean follow-up 
of 28 months of follow-up (table not provided).
Discussion
In the question of EVAR versus OSR, the RCT evidence is 
limited. The enrolment period for DREAM was November 
2000 to December 2003, and for EVAR 1 enrolment periods 
were September 1999 to December 2003. Based on this work 
and earlier work (Franks et al 2007), this RCT evidence may 
be dated. Future evidence may come from an ongoing large 
multi-center trial, The Open Versus Endovascular Repair 
(OVER) Trial for Abdominal Aortic Aneurysms, which had 
an enrolment period, beginning in 2001 and ending in 2010. 
The recruitment period will be more up-to-date and thus, 
based on the results from this analysis, we should expect 
lower perioperative mortality rates in both EVAR and OSR, 
but similar mortality differences, as well as lower rates of 
endoleaks and ischemia. In the absence of more RCTs, obser-
vational data may provide the only current evidence.
There are some differences in evidence in nRCTs and 
RCTs. There are baseline imbalances that exist in nRCTs. In 
nRCTS, lower rates of outcomes are reported for all measures 
except limb ischemia which is higher in EVAR. A recent 
report has identiﬁ  ed that there are only small differences 
Table 3 Surgical outcomes
Studies
RCT
WMD
4
nRCT
WMD
75
Multi-center
WMD
16
Single center
WMD
59
Low volume
WMD
31
High volume
WMD
28
Suitable
WMD
5
High risk
WMD
8
Operating time (hours) −0.30* −0.85 −1.03* −0.80 −0.40 −1.08* −2.70 −0.39
Blood loss (mL) −1243* −1285* −1216* −1306* −1413* −1178* −1629* −2261*
Intensive care (days) −4.81 −2.24 −2.12* −2.32 −2.07 −2.22 −0.80* −1.94*
Length of stay (days) −5.55* −5.54* −5.79* −5.36* −5.97* −4.93* −12.30* −6.80*
Notes: *statistically signiﬁ  cant: p-value 0.05. Both WMD and odds ratio were calculated with patient weights.
Abbreviations: WMD, weighted mean difference; EVAR-OSR, odds ratio (EVAR/OSR).
Table 4 Local/vascular complications
Studies RCT
Odds
ratio
4
nRCT
Odds
ratio
75
Multi-center
Odds
ratio
16
Single center
Odds
ratio
59
Low volume
Odds
ratio
31
High volume
Odds
ratio
28
Suitable
Odds
ratio
5
High risk
Odds
ratio
8
Graft infection 0.506 4.646 – 3.518 – 2.458 – –
Graft thrombosis – 3.088* 2.242 2.981 – 3.051* ––
Aortenteric ﬁ  stula – – – – – – – –
Arterial/graft obstruction – 2.853* – 2.890* 1.566 8.952* 2.635 –
Groin minor – 2.869* – 3.035* 3.777* 1.735 2.269 –
Groin/wound infection – 0.871 0.491* 1.197 2.16* 0.977 0.738 –
Hemorrhage – major 0.165* 0.297* 0.251* 0.288* 0.305* 0.269* 1.747 –
Hemorrhage – moderate – 0.421* – 0.421* 0.344* 0.577 – 0.177*
Pseudoaneurysm – abdominal – 0.151* – 0.209 – – – –
Thromboembolism – major 2.047 0.229* – 0.249* 0.521 0.203* ––
Thromboembolism – moderate – 2.435* – 2.297* 1.613 7.200* ––
Wound major 1.018 0.570 0.380* 0.230 – 0.232 – –
Notes: *statistically signiﬁ  cant: p-value 0.05. Both WMD and odds ratio were calculated with patient weights.
Abbreviations: WMD, weighted mean difference; EVAR-OSR, odds ratio (EVAR/OSR).Vascular Health and Risk Management 2008:4(5) 1019
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between one large registry (Eurostar) and one large RCT 
(DREAM) (Leurs et al 2007).
There are a number of large multi-center studies, includ-
ing the Eurostar registry, Lifeline Registry for post device 
trial outcomes, and the large multi-center device trials. Also 
present are state, veteran affairs, and US national registries. In 
this study, care was taken to exclude the single center studies 
that make up the device trial evidence. There are some 
baseline differences between the multi-center and single 
center evidence. However, outcomes are mostly similar; 
the exceptions being that endoleaks (type 1 and type 2 
endoleaks) are reportedly higher in single center studies.
The difference between low and high volume centers 
have been reported for other cardiac procedures (Narayan 
et al 2004) and for AAA repair (Bush et al 2006). In this 
report, there were no differences in baseline differences in 
AAA diameter or age, and slightly more ASA IV patients 
in EVAR in low volume centers. Balancing this is that high 
volume centers had more patients receiving EVAR with 
smoking history, hyperlipidemia and other comorbidities. 
This translates into similar outcomes in low volume and high 
volume centers, with the exception of chronic renal failure 
being higher in EVAR for high volume centers.
Studies that have patients, who are suitable for both 
EVAR and OSR should have results similar to RCTs because 
of similar anatomical suitability. Collectively, the total 
number of these patients is the same as an RCT (larger than 
DREAM, smaller than EVAR 1). Mortality difference and 
cardiac, pulmonary and renal outcomes are similar to the 
RCTs. One key difference is the total length of hospital stay, 
which is much higher in EVAR in the nRCT suitable patients. 
This suggests that the differences in ASA III or IV lead to 
differences in OR times, ICU stay and hospital stay.
The RCTs and most nRCTs have a mixed population, with 
high risk and low risk patients. In this report, 8 studies that 
looked exclusively at high-risk patients were identiﬁ  ed, These 
high risk patients incurred a lower rate of cardiac and pulmo-
nary problems in EVAR than OSR. This suggests a signiﬁ  cant 
beneﬁ  t for high risk patients in terms of reduced systemic 
outcomes even when they are at a higher relative risk.
Long term data was analyzed to compare EVAR versus 
OSR for long term mortality. No statistical difference was found 
for up to 36 months. Almost all recent evidence has reported 
no signiﬁ  cant difference in long term mortality (Drury 
et al 2005; Ho et al 2006). Differences that existed earlier 
(Walschot et al 2002) no longer exist.
Outcomes reported for EVAR have been improving over 
time and there are a number of reasons for this. First, there 
has been improvements in outcomes for EVAR surgical pro-
cedures through an evolving experience curve (Forbes et al 
2004) preselecting suitable patients that would beneﬁ  t from 
EVAR, or adjusting the device and perioperative adjuvant 
procedures to reduce later complications such as endoleaks 
and limb ischemia. Second, there have been improve-
ments in the EVAR device almost eliminating type 3 or 4 
Table 5 EVAR outcomes
Studies
RCT
4
nRCT
75
Multi-center
16
Single center
59
Low volume
31
High volume
28
Suitable
5
High risk
8
Endoleaks % % % % % % % %
 type1 0 6.27 4.37 7.89 8.47 7.51 15.00 2.22
 type2 5.0 10.57 8.47 12.11 13.51 11.4 5.00 26.67
 type3 0 0.69 0.67 0.72 0.60 0.79 0 1.11
 type4 0 1.07 2.14 0 0 0 0 0
Conversion 1.81 1.49 1.95 0.98 1.09 0.94 0.38 0.36
Graft obstruction n.a. 1.08 0 1.59 5.58 0 14.46 0
Graft kinks or folds n.a. 0.53 0.64 0.45 1.35 0 0 0
Graft migration n.a. 0.61 0.35 0.86 2.02 0.17 0 8.33
Table 6 Endoleaks and limb ischemia
Outcome Meta-analysis %
(95% CI)
Meta-regression
trend % (P-value)
Endoleak
  Type 1 6.77% (3.26% to 10.27%) −0.76% (P = 0.39)
  Type 2 9.78% (6.76% to 12.79%) −0.47% (P = 0.59)*
  Type 3 0.68% (0.43% to 0.94%) +0.17% (P = 0.01)
  Type 4 0.33% (0.12% to 0.54%) −0.22% (P  0.01)
Limb ischemia
(EVAR-OSR)
0.95% (0.94% to 0.96%) −0.02% (P  0.01)
Notes: Coefﬁ  cient on time trend in meta-regression; *: one outlier with 100% rate 
of Type 2 Endoleak was removed from analysis.Vascular Health and Risk Management 2008:4(5) 1020
Hopkins et al
endoleaks (device failures). Third, there has been an 
increased tendency to have lower risk patients receive 
EVAR (Anderson et al 2004). In comparison, other studies 
have reported improving outcomes for patients that receive 
OSR (Black and Cambria 2006). This is the ﬁ  rst study that 
demonstrates that the mortality risk difference is only slightly 
falling with time. This is supported by earlier comparative 
meta-analysis and recent comparative meta-analysis.
EVAR highlights the problem of performing a ﬁ  xed point 
in time meta-analysis of a procedure that is continually evolv-
ing and technologically improving over time.
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The authors report no conﬂ  icts of interest in this work.
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